Tag: LP1R
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
Heart failure event-related greenhouse gas emissions estimated at 9.45 and 9.70 kg CO2e per patient per year for GLP-1 RA and placebo users, respectively
GLP-1 Receptor Agonist Use Linked to Reduced Overall Risk for Cancer in Adults With...
Significantly lower risks seen for endometrial cancer, ovarian cancer, meningioma; nonsignificantly increased risk seen for kidney cancer
26.5 Percent of Adults With Diabetes Used GLP-1 RA Injectables in 2024
Hispanic, Black non-Hispanic, White non-Hispanic adults more likely to use GLP-1 RA injectables than Asian non-Hispanics
GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR
Study IDs Barriers to GLP-1 Receptor Agonist Use in Adolescents, Young Adults
A number of young adults eligible for GLP-1 RAs are uninsured
GLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
Association seen in seniors with type 2 diabetes; greater associations seen for semaglutide and liraglutide
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA versus DPP4i users
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
GLP-1 receptor agonist use linked to lower risk for overall dementia, Alzheimer disease, nonvascular dementia compared with metformin
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
Significantly lower risks seen for those receiving GLP-1 receptor agonists compared with other antidiabetic drugs
GLP-1 Receptor Agonists May Improve Outcomes in Idiopathic Intracranial Hypertension
GLP-1 receptor agonists linked to lower medication use and reduced headaches, visual disturbances or blindness, and papilledema
